



1449 IRSY. 7.801 U.S. Department of Commerce Patent and Trademark Office	ATTORNEY DOCKET NO.	2488-1-012PCT/US
	SERIAL NO.	10/558,937
LIST OF DOCUMENTARY INFORMATION CITED BY APPLICANT (Use several sheets if necessary)	APPLICANT	Miles Andrew NUNN
	FILING DATE	December 1, 2005
	GROUP	Not yet assigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
/H.A.R./	BA	WO 93/17099	9/2/93	PCT			

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

/H.A.R./	CA	Bao et al., Transgenic Expression of a Soluble Complement Inhibitor Protects Against Renal Disease and Promotes Survival in MRL/lpr Mice, J. Immunol., 168:3601-3607 (2002)					
↓	CB	Bedford et al., Influence of complement depletion on sperm function in the female rabbit, J. Reprod. Fertil., 69:523-528 (1983)					
	CC	Biesecker et al., Derivation of RNA aptamer inhibitors of human complement C5, Immunopharmacology, 42:219-230 (1999)					
	CD	Cicchetti et al., Combined Inhibition of Apoptosis and Complement Improves Neural Graft Survival of Embryonic Rat and Porcine Mesencephalon in the Rat Brain, Exp. Neurol., 177:376-384 (2002)					

EXAMINER: /Hope Robinson/	DATE CONSIDERED: 04/11/2009
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	



Form PTO-1449 IRSY. 7.801 U.S. Department of Commerce Patent and Trademark Office LIST OF DOCUMENTARY INFORMATION CITED BY APPLICANT (Use several sheets if necessary)	ATTORNEY DOCKET NO.	2488-1-012PCT/US
	SERIAL NO.	10/558,937
	APPLICANT	Miles Andrew NUNN
	FILING DATE	December 1, 2005
	GROUP	Not yet assigned

/H.A.R./	CE	Diamond et al., Human CD59 expressed in transgenic mouse hearts inhibits the activation of complement, 3:305-312 (1995)
	CF	Ember et al., Characterization of Complement Anaphylatoxins and Their Biological Responses, In: The Human Complement System in Health and Disease, Volanakis, J.E., Frank, M.M. (Eds.), Marcel Dekker, New York, 241-284
	CG	Fecke et al., Protection of hDAF-transgenic porcine endothelial cells against activation by human complement: role of the membrane attack complex, Xenotransplantation, 9:97-105 (2002)
	CH	Florante et al., Low molecular weight dextran sulfate prevents complement activation and delays hyperacute rejection in pig-to-human xenotransplantation models, Xenotransplantation, 8:24-35 (2001)
	CI	Fitch et al., Pharmacology and Biological Efficacy of a Recombinant, Humanized, Single-Chain Antibody C5 Complement Inhibitor in Patients Undergoing Coronary Artery Bypass Graft Surgery With Cardiopulmonary Bypass, Circulation, 100:2499-2506 (1999)
	CJ	Frei et al., Generation of a monoclonal antibody to mouse C5 application in an ELISA assay for detection of anti-C5 antibodies, Molecular Cell. Probes, 1:141-149 (1987)
	CK	Giclas, P.C., Classical pathway evaluation and alternative pathway evaluation (sections 13.1. and 13.2), In: Current Protocols in Immunology, Editors: J.E. Coligan, A.M. Kruisbeek, D.H. Margulies, E.M. Shevach and W. Strober, Vol. 3 (1994)
	CL	Homeister et al., Effects of Complement Activation in the Isolated Heart, Circulation Research, 71:303-319 (1992)
	CM	Hebello et al., Suppression of the Immune Response by a Soluble Complement Receptor of B Lymphocytes, 254:102-105 (1991)
	CN	Jarvis et al., IgM rheumatoid factor and the inhibition of covalent binding of C4b to IgG in immune complexes, Clin. Exp. Rheumatol., 11:135-141 (1993)
▼	CO	Kohl, Anaphylatoxins and infectious and non-infectious inflammatory diseases, Molecular Immunology, 38:175-187 (2001)

EXAMINER: /Hope Robinson/	DATE CONSIDERED: 04/11/2009
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	



Form PTO-1449 IRSY. 7.801 U.S. Department of Commerce Patent and Trademark Office LIST OF DOCUMENTARY INFORMATION CITED BY APPLICANT (Use several sheets if necessary)	ATTORNEY DOCKET NO.	2488-1-012PCT/US
	SERIAL NO.	10/558,937
	APPLICANT	Miles Andrew NUNN
	FILING DATE	December 1, 2005
	GROUP	Not yet assigned

/H.A.R./	CP	Kontinen et al., Complement in acute and chronic arthritides: assessment of C3c, C9 and protectin (CD59) in synovial membrane, Ann. Rheum. Dis., 55:888-894 (1996)
	CQ	Kroshus et al., A recombinant soluble chimeric complement inhibitor composed of human CD46 and CD55 reduces acute cardiac tissue injury in models of pig-to-human heart transplantation, Transplantation, 69:2282-2289 (2000)
	CR	Link et al., Selection of phage-displayed anti-guinea pig C5 or C5a antibodies and their application in xenotransplantation, Mol. Immunol., 36:1235-1247 (1999)
	CS	Miletic, et al., Complement activation in stored platelet concentrates, Transfusion, 33:150-154 (1993)
	CT	Mulligan et al., Endothelial Targeting and Enhanced Antiinflammatory Effects of Complement Inhibitors Possessing Sialyl Lewis ^x Moieties, J. Immunol., 162:4952-4959 (1999)
	CU	Paesen et al., Tick Histamine-Binding Proteins: Isolation, Cloning, and Three-Dimensional Structure, Molecular Cell, 3:661-671 (1999)
	CV	Paesen et al., Tick histamine-binding proteins: lipocalins with a second binding cavity, Biochim. Biophys. Acta., 1482:92-101 (2000)
	CW	Pratt et al., Effects of Complement Inhibition with Soluble Complement Receptor-1 on Vascular Injury and Inflammation during Renal Allograft Rejection in the Rat, Am. J. Pathol., 149:2055-2066 (1996)
	CX	Rehrig et al., Complement Inhibitor, Complement Receptor 1-Related Gene/Protein γ-Ig Attenuates Intestinal Damage After the Onset of Mesenteric Ischemia/Reperfusion Injury in Mice, J. Immunol., 167:5921-5927 (2001)
	CY	Ribeiro, Ixodes dammini: Salivary Anti-complement Activity, Exp. Parasitol., 64:347-353 (1987)
↓	CZ	Rollins et al., Retroviral Vector Producer Cell Killing in Human Serum Is Mediated by Natural Antibody and Complement: Strategies for Evading the Humoral Immune Response, Hum. Gene Ther., 7:619-626 (1996)

EXAMINER: /Hope Robinson/	DATE CONSIDERED: 04/11/2009
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Form PTO-1449 IRSY. 7.801 U.S. Department of Commerce Patent and Trademark Office	ATTORNEY DOCKET NO.	2488-1-012PCT/US
	SERIAL NO.	10/558,937
	APPLICANT	Milcs Andrew NUNN
	FILING DATE	December 1, 2005
LIST OF DOCUMENTARY INFORMATION CITED BY APPLICANT (Use several sheets if necessary)	GROUP	Not yet assigned

/H.A.R./	DA	Rollins et al., Anti-C5 Single Chain Antibody Therapy Blocks Complement & Leukocyte Activation and Reduces Myocardial Tissue Damage in CPB Patients, Mol. Immunol., 35:397-397 (1998)
	DB	Sahu et al., Complement inhibitors: a resurgent concept in anti-inflammatory therapeutics, Immunopharmacology, 49:133-148 (2000)
	DC	Sandoval et al., Distal Recognition Site for Classical Pathway Convertase Located in the C3aC/Netrin Module of Complement Component C5, The Journal of Immunol., 165:1086-1073 (2000)
	DD	Schiller et al., Expression of a Soluble Complement Inhibitor Protects Transgenic Mice from Antibody-Induced Acute Renal Failure, J. Am. Soc. Nephrol., 12:71-79 (2001)
	DE	Smith et al., Membrane-targeted complement inhibitors, Mol. Immunol., 38:249-255 (2001)
	DF	Solomon et al., Transmission of antibody-induced arthritis is independent of complement component 4(C4) and the complement receptors 1 and 2 (CD21/35), Eur. J. Immunol., 32:644-651 (2002)
	DG	Tanaka et al., Effect of Anticomplement Agent K76 COOH On Hamster-To-Rat and Guinea Pig-to-Rat Heart Xenotransplantation, Transplantation, 62:681-688 (1996)
	DH	Thomas et al., Sulfonated Dextran Inhibits Complement Activation and Complement-Dependent Cytotoxicity in an <i>in vitro</i> Model of Hyperacute Xenograft Rejection, Mol. Immunol., 33:643-648 (1996)
	DI	Vakeva et al., Myocardial Infarction and Apoptosis After Myocardial Ischemia and Reperfusion-Role of the Terminal Complement Components and Inhibition by Anti-C5 Therapy, Circulation, 97:2259-2267 (1998)
	DJ	Valenzuela et al., Purification, Cloning, and Expression of a Novel Salivary Anticomplement Protein from the Tick, <i>Ixodes scapularis</i> , J. Biol. Chem., 275:18717-18723 (2000)
	DK	Wang et al., Anti-C5 monoclonal antibody therapy prevents collagen-induced arthritis and ameliorates established disease, Proc. Natl. Acad. Sci. USA, 92:8955-8959 (1995)

EXAMINER: /Hope Robinson/	DATE CONSIDERED: 04/11/2009
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	





Form PTO-1449 IRSY. 7.801 U.S. Department of Commerce Patent and Trademark Office LIST OF DOCUMENTARY INFORMATION CITED BY APPLICANT (Use several sheets if necessary)	ATTORNEY DOCKET NO.	2488-1-012PCT/US
	SERIAL NO.	10/558,937
	APPLICANT	Miles Andrew NUNN
	FILING DATE	December 1, 2005
	GROUP	Not yet assigned

/H.A.R./	DL	Wang et al., Amelioration of lupus-like autoimmune disease in NZB/WF ₁ mice after treatment with a blocking monoclonal antibody specific for complement component C5, Proc. Natl. Acad. Sci. USA, 83:8563-8568 (1996)
	DM	Ward et al., Use of Animal Models to Define Complement Functions, In: Contemporary Immunology: Therapeutic Interventions in the Complement System, Lambris, J.D., Holers, V.M. (Eds.), Humana Press, Totowa, NJ, 237-253 (2000)
	DN	Weisman et al., Soluble Human Complement Receptor Type 1: <i>In vivo</i> Inhibitor of Complement Suppressing Post-Ischemic Myocardial Inflammation and Necrosis, Science, 249:146-151 (1990)
	DO	Wyss-Coray et al., Prominent neurodegeneration and increased plaque formation in complement-inhibited Alzheimer's mice, Proc. Natl. Acad. Sci. USA, 99:10837-10842 (2002)
	DP	Zhang et al., Targeting of Functional Antibody-Decay-accelerating Factor Fusion Proteins to a Cell Surface, J. Biol. Chem., 276:27290-27295 (2001)
	DQ	McKenzie et al., Regulation of Complement Activity by Vaccinia Virus Complement-Control Protein, J. of Infectious Diseases, 166:1245-1250 (1992)
	DR	Asghar et al., Inhibition of Complement by a Series of Substituted 2-Aryl-1, 3-Indandiones: Interaction with the Fifth Component of Complement, Molecular Immunology, 23:459-465 (1986)
	DS	White, Jr. et al., Suppression of mouse complement activity by contaminants of technical grade pentachlorophenol, Agents and Actions, 16:385-392 (1985)
	DT	Feuillard et al., Comparative study of <i>in vitro</i> inhibition of activation of the classical and alternative pathways of human complement by the magnesium and sodium salts of the anti-inflammatory peptide N-acetyl-aspartyl-glutamic acid (NAAGA), Agent and Actions, 32:343-346 (1991)
↓	DU	Baranda et al., Purification, N-terminal sequencing and diagnostic value of the major antigens of <i>Ornithodoros erraticus</i> and <i>O. moubata</i> , Veterinary Parasitology, 87:193-206 (2000)

EXAMINER: /Hope Robinson/	DATE CONSIDERED: 04/11/2009
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Form PTO-1449 IRSY. 7.801 U.S. Department of Commerce Patent and Trademark Office LIST OF DOCUMENTARY INFORMATION CITED BY APPLICANT (Use several sheets if necessary)	ATTORNEY DOCKET NO.	2488-1-012PCT/US
	SERIAL NO.	10/558,937
	APPLICANT	Miles Andrew NUNN
	FILING DATE	December 1, 2005
	GROUP	Not yet assigned

[illegible]

EXAMINER:	/Hope Robinson/	DATE CONSIDERED:	04/11/2009
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>			